Inhibitory Effect of PPARγ Agonist on the Proliferation of Human Pterygium Fibroblasts

作     者：邹媛 张明昌 Yuan ZOU 1,Mingchang ZHANG 2# 1 Department of Ophthalmology,the First Clinical Medical Science College of China Three Gorges University,Yichang 443003,China 2 Department of Ophthalmology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China

作者机构：Department of Ophthalmologythe First Clinical Medical Science College of China Three Gorges University Department of OphthalmologyUnion HospitalTongji Medical CollegeHuazhong University of Science and Technology 

出 版 物：《Journal of Huazhong University of Science and Technology(Medical Sciences)》 (华中科技大学学报（医学英德文版）)

年 卷 期：2010年第30卷第6期

页      面：809-814页

核心收录：

学科分类：1002[医学-临床医学] 100212[医学-眼科学] 10[医学] 

基　　金：supported by a grant from the Natural Sciences Foundation of Hubei Province China(No.2008CDA055) 

主　　题：DK2 peroxisome proliferator-activated receptor γ pterygium human pterygium fibroblasts proliferation inhibition 

摘      要：The effects of DK2,a peroxisome proliferator-activated receptor γ agonist,on cultured human pterygium fibroblasts (HPFs) in virto were *** HPFs were incubated with 0-200 μmol/L DK2 for 12-72 *** MTT method was used to assay the bio-activity of DK2 at different doses and *** cytotoxic effect of DK2 was measured by LDH release *** cell cycle distribution and apoptosis were flow cytometrically *** expression of proliferating cell nuclear antigen (PCNA) in each group was detected by real-time PCR (RT-PCR) and Western *** results showed that administration of 1-75 μmol/L DK2 for 12-72 h could significantly inhibit HPF proliferation in a dose-and time-dependent ***2-treated cells did not release significant amount of LDH as compared with rosiglitazone-treated *** treatment with DK2 at concentrations of 15,25 μmol/L for 24 h,the number of HPFs in G 0 /G 1 phase was significantly increased while that in S phase was significantly decreased (P0.05),leading to arrest at G 0 /G 1 *** apoptosis rates of HPF cells in drug-treated groups were significantly higher than the rate of control group (P0.05).At the dosage range between 15-25 μmol/L,DK2 could inhibit the expression of PCNA mRNA and protein in HPFs in a dose-dependent fashion (P0.05).It was concluded that PPARγ agonist can significantly inhibit HPF proliferation,resulting in the arrest at G 0 /G 1 phase,induce the apoptosis of HPFs,and suppress the synthesis of PCNA,in dose-and time-dependent manners.